Showing 2721-2730 of 4063 results for "".
- HHS Bids $250 Million Contract Meant to ‘Defeat Despair and Inspire Hope’ on Coronavirushttps://modernod.com/news/hhs-bids-250-million-contract-meant-to-defeat-despair-and-inspire-hope-on-coronavirus/2478236/As the presidential election fast approaches, the Department of Health and Human Services is bidding out a more than $250 million contract to a communications firm as it seeks to “defeat despair and inspire hope” about the coronavirus pandemic, according to a
- Vision Expo to Host Virtual Career Zone Event on September 22https://modernod.com/news/vision-expo-to-host-virtual-career-zone-event-on-september-22/2478215/Vision Expo announced plans to host the Virtual Career Zone, a virtual networking event designed to connect young professionals and students with prominent optical companies. Set to take place on Tuesday, September 22 from 11-11:55 a.m. EDT, the virtual event is inspired by Vision Expo’s o
- TearClear Raises $22M in Series B Fundinghttps://modernod.com/news/tearclear-raises-22m-in-series-b-funding/2478158/TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Led by Chief Executive Officer Robert Dempsey, T
- Academy 2020 Moves Online Due to COVID-19https://modernod.com/news/academy-2020-moves-online-due-to-covid-19/2478154/As a direct result of the COVID-19 pandemic, the American Academy of Optometry’s (AAO) announced that Academy 2020 Nashville will be held entirely as a virtual meeting renamed Academy 2020 At Home. “We listened to our stakeholders and watched the national health situation very car
- Bausch + Lomb Launches -2.75 Cylinder for Biotrue ONEday for Astigmatism Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-launches-2-75-cylinder-for-biotrue-oneday-for-astigmatism-daily-disposable-contact-lenses/2478129/Bausch + Lomb announced the US launch of the -2.75 cylinder parameter offering for Biotrue ONEday for Astigmatism daily disposable contact lenses, the first and only toric daily disposable with a -2.75 cylinder. This new parameter offering will be available for same day fitting in a standard fit
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd-2/2478113/Regenxbio reported positive 1 year data from patients in Cohorts 4 and 5 of the phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The company plans to initiate a pivotal program for subretinal delivery of RGX-314 in patients with wet AMD by the end of 20
- Sanofi, GSK Gain $2.1 Billion From US Government for Development, Supply of COVID-19 Vaccinehttps://modernod.com/news/sanofi-gsk-gain-2-1-billion-from-us-government-for-development-supply-of-covid-19-vaccine/2478107/Sanofi and GlaxoSmithKline announced that the US government will provide more than $2.1 billion to support further development, manufacturing and delivery of initial doses of the companies’ adjuvanted vaccine against COVID-19. The vaccine candidate is based on Sanofi’s recombinant pro
- The Vision Council Releases 2019 Vision Watch Cataract Reporthttps://modernod.com/news/the-vision-council-releases-2019-vision-watch-cataract-report/2478110/The Vision Council recently released the results of the 2019 VisionWatch Cataract Report. Conducted in December 2019, the study measures changes in consumer behavior related to vision and vision correction after undergoing cataract surgery. The intent of the study was to explore how cataract surg
- US News Releases 2020-21 Best Hospitals Rankings and Special ‘Hospital Heroes’ Serieshttps://modernod.com/news/us-news-releases-2020-21-best-hospitals-rankings-and-special-hospital-heroes-series/2478086/U.S. News & World Report released the 2020-21 Best Hospitals rankings. The 31st editio
- jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosahttps://modernod.com/news/jcyte-announces-phase-2b-results-of-jcell-therapy-in-retinitis-pigmentosa/2478078/jCyte Inc. announced promising results from a phase 2b clinical trial of jCell in retinitis pigmentosa (RP), irrespective of genetic subtype. jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addi